ResultsIQ

ResultsIQ › Latest results › Rubicon Research Limited

Rubicon Research Limited Q4 FY26 earnings call summary

NSE: RUBICON · BSE: 544578

Earnings call of 29 May 2026, summarised by AI from the filing.

22% to 23% range reiterated for coming quarters, including ESOP, Arinna and Pithampur expenses.

Key takeaways

  1. EBITDA guidance 22% to 23% range reiterated for coming quarters, including ESOP, Arinna and Pithampur expenses.
  2. Arinna acquisition Acquired 85% of Arinna Lifesciences for ₹176 cr, enterprise value ₹200 cr, to enter Indian CNS market.
  3. Margin risk Gross margin declined due to internal manufacturing constraints and higher reliance on outsourced manufacturing.

Original filing on BSE

Rubicon Research Limited Q1 FY27 results

As filed: Revenue ₹428 cr, EBITDA ₹125 cr, PAT ₹82.5 cr, EBITDA margin 29.2%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹514 cr, EBITDA ₹119 cr, PAT ₹76.8 cr, EBITDA margin 23.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹514 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +40.9% in 27 days (Nifty 500: +2.0%).
  • Q3 FY26: Revenue ₹476 cr, EBITDA ₹108 cr, PAT ₹72.8 cr, EBITDA margin 22.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹476 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.1% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹336 cr, EBITDA ₹79.0 cr, PAT ₹46.0 cr, EBITDA margin 23.5%. Not scored. No result for the same quarter last year. Share price after the results: −2.8% in 29 days (Nifty 500: −0.4%).

Past price moves after results do not indicate future moves. Not a recommendation.

Rubicon Research Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.